No difference with gabapentin versus placebo following rib fracture in critically ill patients .
A double-blind, randomized controlled trial of gabapentin vs. placebo for acute pain management in critically ill patients with rib fractures
Injury. 2018 Sep;49(9):1693-1698. doi: 10.1016/j.injury.2018.06.00240 patients with one or more rib fractures were randomized to the addition of either gabapentin 300mg or placebo three times daily to a mutlimodal analgesia protocol. Patients were primarily assessed for analgesic outcomes over the first 7 days of treatment, including pain scores and narcotic consumption. Results on these measures demonstrated no significant differences between groups on any day. In addition, data on incentive spirometry during hospitalization, and general and disease-specific quality of life at 1 month follow-up, demonstrated no significant differences between groups. No cases of pneumonia or respiratory failure were noted in either group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
